Inventiva S.A. American Depository Shares IVA

Inventiva SA is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with unmet medical needs.

• GlobeNewswire Inc. 16 jun

  Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development

  Claret Capital Partners has invested €43m in clinical-stage biopharmaceutical company Inventiva as part of a €130m debt financing round. Inventiva is developing lanifibranor, an oral therapy for MASH (metabolic dysfunction-associated steatohepatitis), with Phase 3 trial results expected in Q4 2026. The financing, alongside BlackRock-managed funds, aims to support the company through key clinical and regulatory milestones.

  

• GlobeNewswire Inc. 12 jun

  Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing

  Inventiva completed repayment of €62 million in EIB loans and repurchased EIB warrants for €50 million. The company simultaneously issued €75 million in new debt financing (€35 million convertible bonds and €40 million amortized bonds) from BlackRock and Claret Capital Partners, following a successful €120 million equity offering of ADSs at $4.40 per share.

  

• GlobeNewswire Inc. 9 jun

  Combined General Meeting of June 30, 2026 - Availability of the Preparatory Documents

  Inventiva, a clinical-stage biopharmaceutical company developing oral therapies for MASH, announced the availability of preparatory documents for its Combined General Meeting scheduled for June 30, 2026. The meeting agenda includes a 39th resolution related to a master agreement with the European Investment Bank (EIB) for full repayment of existing loans and buyback of warrants for €50 million, with issuance of new warrants on standard terms. The company is currently evaluating lanifibranor in the NATiV3 Phase 3 clinical trial.

  

• GlobeNewswire Inc. 9 jun

  Information relative au nombre total de droits de vote et d’actions composant le capital social au 22 mai 2026

  Inventiva, a clinical-stage biopharmaceutical company, announced the resumption of trading for its ordinary shares on Euronext Paris and provided information on its Combined General Meeting scheduled for June 30, 2026. As of May 22, 2026, the company had 209,007,475 shares in circulation with 218,082,368 total voting rights.

  

• GlobeNewswire Inc. 9 jun

  Assemblée Générale Mixte du 30 juin 2026 - Modalités de mise à disposition des documents préparatoires

  Inventiva announced the arrangements for its Mixed General Assembly scheduled for June 30, 2026 in Paris. The agenda includes a 39th resolution regarding a master agreement with the European Investment Bank (EIB) signed on June 1, 2026, which involves full repayment of existing EIB loans and repurchase of warrant subscription rights (BSA) for €50 million. The company also adjusted caps for resolutions related to free share allocations and warrant issuances based on recent board decisions.